EUVIMEDEUVIMED entdecken
Crossref

Metoclopramide Use in Nausea and Vomiting of Pregnancy and Risk of Depressive Symptoms as an Adverse Drug Reaction in the Netherlands: A Disproportionality Analysis in a National Spontaneous Reporting Database

Maartje Conijn, Miranda van Tuyl, Eugene P van Puijenbroek, Veronique Y F Maas

Journal of the Academy of Consultation-Liaison Psychiatry · 2026-05 · 67 (3) · 182-190

DOI: 10.1016/j.jaclp.2026.03.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Academy of Consultation-Liaison Psychiatry, 2026-05. Verfasst von Maartje Conijn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department Teratology Information Service, Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands. Hauptthemen laut MEDLINE: Metoclopramide, Antiemetics, Depression, Nausea. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Metoclopramide is widely used for nausea and vomiting of pregnancy and hyperemesis gravidarum. While it is known to cause depressive symptoms as an adverse drug reaction (ADR), it is unclear if pregnancy increases this risk. This study aims to assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to non-pregnant women. METHODS A disproportionality analysis was performed using the national spontaneous ADR reporting system of the Netherlands. All reports of ADRs associated with metoclopramide concerning women aged 15-50 years were included. Based on MedDRA-coded terms and case narratives, pregnancy status was determined. Cases were defined as reports on depressive symptoms. A case review was performed. Disproportionality in reporting between pregnant- and non-pregnant women was evaluated using a reporting odds ratio (ROR) with 95% confidence interval (95% CI). For comparison, two other anti-emetic drugs (ondansetron and meclozine with pyridoxine) were also assessed. RESULTS Reports of depressive symptoms associated with metoclopramide use were reported more often in pregnant women (21.1%) than in non-pregnant women (3.0%) (ROR 8.6; 95% CI 3.2-23.2). In pregnancy-related cases, depressive symptoms were reported more often following metoclopramide exposure (21.1%) compared to exposure to other anti-emetics (7.3%) (ROR 3.4; 95% CI 1.2-9.3). In 33.3% of the pregnancy-related cases, suicidality tendency was reported. Depressive symptoms were often accompanied by other mood related symptoms including anxiety, panic attacks, agitation and restlessness. CONCLUSION Although a causal relationship cannot be established, metoclopramide exposure during pregnancy was associated with increased reporting of depressive symptoms compared to both non-pregnant women and exposure to other anti-emetics during pregnancy. This may be explained by a combination of pregnancy-related factors and the pharmacological mechanism of metoclopramide. Given the frequent co-occurrence of suicidal tendency, awareness of this possible ADR is crucial for early recognition and prompt intervention to prevent symptom progression and improve maternal safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetoclopramideAntiemeticsDepressionNauseaVomitingPregnancy ComplicationsHumansFemalePregnancyNetherlandsAdultAdverse Drug Reaction Reporting SystemsAdolescentYoung AdultMiddle AgedHyperemesis GravidarumDatabases, Factual

Stichwörter der Autor:innen

adverse drug reactiondepressionmetoclopramidenauseapregnancyspontaneous reports

Substanzen

MetoclopramideAntiemetics

Autor:innen und Institutionen

  • Department Teratology Information Service, Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
  • Department Teratology Information Service, Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands; Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, University…
  • Department Teratology Information Service, Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands. Electronic address: v.maas@lareb.nl.

Zitieren

APA

Conijn, M., van Tuyl, M., van Puijenbroek, E. P., & Maas, V. Y. F. (2026). Metoclopramide Use in Nausea and Vomiting of Pregnancy and Risk of Depressive Symptoms as an Adverse Drug Reaction in the Netherlands: A Disproportionality Analysis in a National Spontaneous Reporting Database. Journal of the Academy of Consultation-Liaison Psychiatry, 67(3), 182-190. https://doi.org/10.1016/j.jaclp.2026.03.001

Vancouver

Conijn M, van Tuyl M, van Puijenbroek EP, Maas VYF. Metoclopramide Use in Nausea and Vomiting of Pregnancy and Risk of Depressive Symptoms as an Adverse Drug Reaction in the Netherlands: A Disproportionality Analysis in a National Spontaneous Reporting Database. Journal of the Academy of Consultation-Liaison Psychiatry. 2026;67(3):182-190. doi:10.1016/j.jaclp.2026.03.001

BibTeX
@article{Conijn2026,
  author = {Conijn, Maartje and van Tuyl, Miranda and van Puijenbroek, Eugene P and Maas, Veronique Y F},
  title = {Metoclopramide Use in Nausea and Vomiting of Pregnancy and Risk of Depressive Symptoms as an Adverse Drug Reaction in the Netherlands: A Disproportionality Analysis in a National Spontaneous Reporting Database},
  journal = {Journal of the Academy of Consultation-Liaison Psychiatry},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {182--190},
  doi = {10.1016/j.jaclp.2026.03.001}
}
Kostenlos starten →